


Ryals *et al.*
Atty. Docket PB/5-21215C

REMARKS

Claims 1, 8, 10, 42, 58, and 62 have been amended, claims 2-7, 9, 11-41, 43-57, 60-61, and 63-67 have been canceled without prejudice or disclaimer, and new claims 68-93 have been added. Thus, the pending claims are 1, 8, 10, 42, 58-59, 62, and 68-93. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

No new matter has been added. Therefore, Applicants respectfully request that the instant amendment be entered and receive favorable consideration. The Examiner is invited to telephone the undersigned attorney if any questions or concerns arise during examination.

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicants
Registration No. 38,241

Syngenta Biotechnology, Inc.
P. O. Box 12257
Research Triangle Park, NC 27709-2257
Telephone: 919-541-8587
December 12, 2001

Version With Markings To Show Changes Made

Claims 1, 8, 10, 42, 58, and 62 have been amended as follows:

1. (Amended) A method for protecting a plant from pathogen attack, comprising the steps of:

- (a) providing [an immunomodulated] a plant transformed with a chimeric gene comprising a promoter active in plants operatively linked to a nucleotide sequence encoding a protein involved in the signal transduction cascade leading to systemic acquired resistance in plants, wherein the complement of said nucleotide sequence hybridizes under the following conditions to the coding sequence set forth in SEQ ID NO:6: hybridization in 1% BSA; 520mM NaPO₄, pH7.2; 7% lauryl sulfate, sodium salt; 1mM EDTA; 250 mM sodium chloride at 55°C for 18-24h, and wash in 6XSSC for 15 min. (X3) 3XSSC for 15 min. (X1) at 55°C, wherein said plant exhibits [having] a first level of disease resistance; and
- (b) applying to [said immunomodulated] the plant provided in step (a) [at least one] a microbicide that confers a second level of disease resistance;
- (c) whereby application of said microbicide to said [immunomodulated] plant confers a synergistically enhanced third level of disease resistance that is greater than the sum of the first and second levels of disease resistance.

8. (Amended) A method according to claim 1 [7], wherein said [NIM1] protein comprises the amino acid sequence set forth in SEQ ID NO:2.

10. (Amended) A method according to claim 1 [7], wherein said [DNA molecule] nucleotide sequence comprises the coding sequence set forth in [SEQ ID NO:1.] SEQ ID NO:6.

42. (Amended) A method according to claim 1 [6], wherein said microbicide is a fungicide selected from the following group:

4-[3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl]morpholine ("dimethomorph");
5-methyl-1,2,4-triazolo[3,4-b][1,3]benzothiazole ("tricyclazole");

3-allyloxy-1,2-benzothiazole-1,1-dioxide ("probonazole");
 μ -[2-(4-chlorophenyl)ethyl]-- μ -(1,1-dimethylethyl)-1H-1,2,4-triazole-1-ethanol, ("tebuconazol");
1-[[3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl]-1H-1,2,4-triazole, ("epoxyconazol");
 μ -(4-chlorophenyl)-- μ -(1-cyclopropylethyl)--1H-1,2,4-triazole--1-ethanol, ("ciproconazol");
5-(4-chlorobenzyl)--2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)-cyclopentanol, ("metconazol");
2-(2,4-dichlorophenyl)--3-(1H-1,2,4-triazol-1-yl)-propyl--1,1,2,2-tetrafluoroethyl-ether, ("tetraconazol");
methyl-(E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate, ("ICI A 5504", "azoxystrobin");
methyl-(E)--2-methoximino--2-[μ -(o-tolylloxy)--o-tolyl]acetate, ("BAS 490 F", "cresoxime methyl");
2-(2-phenoxyphenyl)-(E)-2-methoximino--N-methylacetamide);
[2-(2,5-dimethylphenoxyethyl)-phenyl]-(E)--2-methoximino-N-methylacetamide);
(1R,3S/1S,3R)-2,2-dichloro--N-[(R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide, ("KTU 3616");
manganese ethylenebis(dithiocarbamate)polymer-zinc complex, ("mancozeb");
1-[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, ("propiconazole");
1-{2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl}-1H-1,2,4-triazole, ("difenoconazole");
1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole, ("penconazole");
cis-4-[3-(4-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine, ("fenpropimorph");
1-[3-(4-tert-butylphenyl)-2-methylpropyl]-piperidine, ("fenpropidin");
4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine ("cyprodinil");

(RS)-N-(2,6-dimethylphenyl--N-(methoxyacetyl)-alanine methyl ester ("metalaxyl", "ridomil");

(R)-N-(2,6-dimethylphenyl--N-(methoxyacetyl)-alanine methyl ester ("R-metalaxyl");

1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one ("pyroquilon"); and

ethyl hydrogen phosphonate ("fosetyl").

58. (Amended) A method according to claim 1 [6], wherein said microbicide is either a benzothiadiazole compound, an isonicotinic acid compound, or a salicylic acid compound.

62. (Amended) A method according to claim 59 [61], wherein said benzothiadiazole compound is benzo(1,2,3)thiadiazole-7-carbothioic acid *S*-methyl ester.

Claims 2-7, 9, 11-41, 43-57, 60-61, and 63-67 have been canceled without prejudice or disclaimer.

New claims 68-93 have been added